EGFR and non-small cell lung carcinoma: Over the past two decades, treatment with agents targeting EGFR gene mutations, present in approximately 10% of NSCLC cases in the UK, anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) translocations have led to an improved survival of these patients in the metastatic setting [7,11].